It has long been appreciated that estrogenic signaling contributes to breast cancer progression. c-Src is also required for a number of processes involved in tumor progression and metastasis. We have previously identified the K303R mutant estrogen receptor A (ERA) that confers hypersensitivity to low levels of estrogen. Because ERA and c-Src have been shown to interact in a number of different systems, we wanted to evaluate the role of c-Src kinase in estrogen-stimulated growth and survival of ERA-positive breast cancer cells. MCF-7 cells stably expressing the mutant receptor showed increased c-Src kinase activity and c-Src tyrosine phosphorylation when compared with wild-type ERA-expressing cells. A c-Src inhibitor, AZD0530, was used to analyze the biological effects of pharmacologically inhibiting c-Src kinase activity. MCF-7 cells showed an anchoragedependent growth IC 50 of 0.47 Mmol/L, which was increased 4-fold in the presence of estrogen. In contrast, cells stably expressing the mutant ERA had an elevated IC 50 that was only increased 1.4-fold by estrogen stimulation. The c-Src inhibitor effectively inhibited the anchorage-independent growth of both of these cells, and estrogen was able to reverse these effects. When cells were treated with suboptimal concentrations of c-Src inhibitor and tamoxifen, synergistic inhibition was observed, suggesting a cooperative interaction between c-Src and ERA. These data clearly show an important role for ERA and estrogen signaling in c-Src -mediated breast cancer cell growth and survival. Here, we show that c-Src inhibition is blocked by estrogen signaling; thus, the therapeutic use of c-Src inhibitors may require inhibition of ERA in estrogen-dependent breast cancer.
Introduction
Estrogen signaling has long been known to stimulate a variety of effects, including cell growth and survival, two important mechanisms in the progression of cancer. These effects are mediated through cognate receptors of estrogen, estrogen receptors (ER) a and h. Although ERa is required for normal mammary gland development (1), work with knockout mice has not shown a requirement for ERh in mammary gland development (2) . Interestingly, 70% of breast tumors express ERa (3, 4) , making the estrogen pathway an effective target for a large number of clinical therapeutics.
We have previously identified an ERa A908G somatic mutation in one third of premalignant breast lesions (5) , and others have found the mutation at a low frequency in invasive breast cancers (6) . The resulting A908G transition leads to the substitution of the 303 lysine for an arginine (K303R; ref. 5); this lysine is an important acetylation site in ERa (7) and is involved in regulation of the S305 protein kinase A phosphorylation site (8) . Furthermore, this mutated receptor has reduced binding to corepressors and increased binding to coactivators, which may play a role in its hypersensitivity to estrogen signaling (5) . Although the K303R-ERa mutation is one of many receptor variants that have been identified (for a complete review, see ref. 9) , it is the only somatic mutation that has been identified in a large number of patient samples.
The nonreceptor tyrosine kinase c-Src has been implicated in a number of different cancers, including breast, colon, and pancreatic cancers (for a complete review, see ref. 10) . A number of different groups have shown that c-Src protein is up-regulated in approximately half of breast cancers versus normal mammary epithelium (11, 12) . Additionally, transgenic mice expressing a mouse mammary tumor virus v-Src develop mammary hyperplasias (13) , whereas knocking out the c-Src gene delays mammary tumorigenesis of polyoma middle T antigen -induced tumors (14) . In contrast, knockout of the related c-Yes proto-oncogene did not affect mammary tumorigenesis in this model (14) . Collectively, these data show an important and specific role for c-Src in mammary tumor development.
In 1993, Miggliaccio et al. (15) showed that estrogen stimulation of MCF-7 breast cancer cells led to an immediate tyrosine phosphorylation and activation of the c-Src kinase. It was later shown that estrogen stimulation can activate a number of other classic signal transduction pathways, such as phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2 (16, 17) , and that ligand-induced ERa activation recruited a c-Src/p85/ERa complex (16, 18) . In addition to ERa signaling to c-Src, c-Src can phosphorylate ERa on tyrosine 537 (19) . Because of the two-way crosstalk between these two proteins, the aberrant activation of either protein could lead to feedback loops that could significantly influence cellular signaling.
Estrogen signaling stimulates growth and survival in ERa-positive breast cancer cells, and these mechanisms may involve the non -receptor tyrosine kinase c-Src. We thus sought to determine if blockade of c-Src kinase activity could inhibit estrogen-stimulated growth and survival of ERa-positive breast cancer cells. AZD0530 is a novel, potent, and highly selective Src/Abl kinase inhibitor (20) . Here, we show that MCF-7 breast cancer cells respond to c-Src inhibition with reduced anchorage-dependent growth and reduced ability to form colonies in soft agar. Additionally, in the presence of estrogen, cells are less sensitive to c-Src inhibition. We also show that cells expressing the hypersensitive K303R-ERa mutation have elevated c-Src kinase activity and are less sensitive to c-Src inhibition both in the presence and absence of estrogen when compared with cells expressing only the wild-type (WT) ERa. When suboptimal concentrations of AZD0530 and tamoxifen were tested, synergistic inhibition of anchorageindependent growth was observed. Collectively, these data show that inhibition of c-Src may be an effective therapeutic strategy for ERa-positive breast cancer; however, estrogen signaling may alter the ability of c-Src inhibitors to block cell growth.
Materials and Methods

Chemicals
The c-Src inhibitor AZD0530 was provided by Astra Zeneca and dissolved in DMSO (20) . AZD0530 was diluted in tissue culture medium, and the corresponding DMSO controls had no effect on the analyses done. G418 and all cell culture reagents were purchased from Life Technologies (Grand Island, NY). Tamoxifen (4-hydroxytamoxifen) was purchased from Sigma (St. Louis, MO) and the stock solution was dissolved in ethanol at 10 À3 mol/L.
Cell Culture Conditions MCF-7 breast cancer cells were maintained on plastic in MEM supplemented with 10% fetal bovine serum (FBS), 0.1 mmol/L nonessential amino acids, 2 mmol/L L-glutamine, 50 units/mL penicillin/streptomycin (Life Technologies), at 37jC with 5% CO 2 /95% air. Unless otherwise noted, cells were passaged and removed from flasks when 70% to 80% confluent. For cell passage, cells were rinsed with PBS and trypsinized in 0.05% trypsin and 0.02% EDTA for 2 min at 37jC. Trypsin activity was quenched with the addition of medium containing 10% FBS.
Generation of Stable WT ERA and K303R-ERAÊ xpressing Cells Generation of the yellow-fluorescent protein (YFP) -tagged expression constructs, YFP-WT ERa and YFP-K303R-ERa, has been previously described (8) . MCF-7 cells were stably transfected using Fugene according to the manufacturer's instructions (Roche, Indianapolis, IN), and individual clones were isolated and expanded with G418 selection. Stably transfected clones were screened for expression of the exogenous ERa by immunoblot analysis. One clone stably expressing YFP-WT ERa and one clone stably expressing YFP-K303R-ERa with similar levels of the exogenous YFP-ERa and endogenous ERa were chosen for further analysis.
Immunoprecipitation and Immunoblot Analysis Cells were plated in six-well dishes for immunoblot analysis (3 Â 10 5 per plate) or in 10-cm plates for immunoprecipitation (3 Â 10 6 per plate) in MEM supplemented with 10% FBS. Cells were then incubated overnight at 37jC in 5% CO 2 , followed by 48 h starvation in phenol red -free MEM with 5% charcoal-stripped FBS. Proteins, either immunoprecipitated or whole-cell lysate, were heated in Laemmli's sample buffer for 5 min, separated by 7.5% SDS-PAGE, transferred to nitrocellulose membrane (Whatman, Inc., Sanford ME), and probed with the following antisera, as indicated: anti-Src antisera (clone GD11, 1:1,000) and anti-phosphotyrosine antisera (4G10, 1:5,000) from Upstate Biotechnology Inc. (Lake Placid, NY); anti -phospho-Fak antisera (pY861, 1:1,000) and antiphospho-c-Src antisera (pY418, 1:1,000) from Biosource (Camarillo, CA); anti-Fak antisera (clone 77, 1:1,000) from BD Biosciences (San Jose, CA); anti-tubulin antisera (clone D66, 1:1,000) from Sigma-Aldrich (St. Louis, MO); and antiERa (clone 6F1, 1:1,000) from NovaCastra (Newcastle upon Tyne, United Kingdom). Antisera were diluted in TBST (TBS/0.1% Tween 20, v/v) with 5% dried milk or 5% bovine serum albumin. Peroxidase-conjugated secondary antisera, goat anti-mouse anti-serum (1:3,000; Amersham Biosciences; Piscataway, NJ), and goat anti-rabbit antiserum (1:3,000; Amersham Biosciences) were used to detect the respective primary antibodies, and immunoreactive proteins were visualized with ECL chemiluminescence technology (Alpha Innotech, San Leandro, CA). Autoradiographic protein levels were quantified in the linear range of the film by scanning the image using a Canon LicoScan scanner and analyzing with the Scion Image c-Src and ERa Synergism software program (Scion Corp., Frederick, MD). Each sample measured was calculated as the ratio of the average area of the phosphorylated protein over the average area of the respective total protein levels.
Cell Proliferation as Measured by 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide Analysis Cells were serum-starved for 48 h in phenol red -free MEM with 5% charcoal-stripped FBS before plating. Cells (3,000 per well) were plated into each well of a 96-well plate and allowed to adhere for 8 h before the addition of increasing concentrations of AZD0530 and estrogen (10 À9 mol/L). Seventy-two hours later, 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT; thiazolyl blue) was added to each well and incubated at 37jC and 5% CO 2 for 2 h followed by medium removal and solubilization in 100 AL DMSO. The resulting color change was read at 570 nm and calculated as absorbance above background. Each experiment contained 12 different doses of AZD0530 in quadruplicate. A minimum of three experiments was combined for IC 50 calculations. The absorbance readings were used to determine the IC 50 using GraphPad Prism 4 (GraphPad Software, Inc., San Diego, CA). Briefly, values were log-transformed, then normalized, and nonlinear regression analysis was used to generate a sigmoidal dose-response curve to calculate IC 50 values for each cell line.
Agarose Colony-Forming Assay Cells (5,000 per well) were plated in 1.5 mL of 0.3% agarose, 5% charcoal-stripped FBS in phenol red-free MEM, with a 0.6% agarose base in six-well plates, with various concentrations, as indicated, of AZD0530, tamoxifen, and estrogen. Cells were then incubated at 37jC and 5% CO 2 with fresh medium added every 3 days. After 14 days, 150 AL of MTT were added to each well and allowed to incubate at 37jC for 4 h. Plates were then placed in 4jC overnight and colonies >50 Am in diameter were quantitated.
Statistical AnalysisTests for Synergy To determine if suboptimal concentrations of tamoxifen and AZD0530 synergistically inhibit cell growth, a modelfree test for synergy was used based on two simultaneous one-sided t tests comparing each of the single-agent doses of AZD0530 (1 Amol/L) and tamoxifen (10 À8 mol/L) with a combined regimen of the two drugs at suboptimal doses (21) . Additionally, dose levels of AZD0530 (0, 0.1, and 1 Amol/L) and tamoxifen (0, 10 À9 , and 10 À8 mol/L) were used in an ANOVA model to assess the effect of AZD0530 or tamoxifen alone and the interaction between the two drugs.
c-Src Immunocomplex Kinase Assay Cells (3 Â 10 6 ) were plated in 10-cm plates with MEM supplemented with 10% FBS and incubated for 24 h at 37jC and 5% CO 2 . Cells were then serum-starved for 48 h in phenol red -free MEM supplemented with 5% charcoalstripped FBS followed by treatment with 10 À9 mol/L estrogen for 10 min before lysis in 50 mmol/L HEPES (pH 7.0), 150 mmol/L NaCl, 1.5 mmol/L MgCl 2 , 1 mmol/L EGTA, 10 mmol/L NaPPi, 1% glycerol (v/v), 0.1% Triton X-100 (v/v), 1 mmol/L Na 3 VO 4 , and 1:200 protease inhibitor cocktail tablet (22) . Immunocomplex kinase assays were done on c-Src immunoprecipitated from 500 Ag of total cellular protein with 1 Ag anti-Src antisera (clone 327) and 50 AL of 10% (w/v) Pansorbin cells (Calbiochem, San Diego, CA) with rotation at 4jC for 2 h. Immunoprecipitated pellets were washed thrice with immunocomplex kinase assay wash buffer [0.1% Triton X-100, 150 mmol/L NaCl, and 10 mmol/L NaPO 4 (pH 7.0); ref . 22] . Ten microliters of 100 Ag/mL acid -denatured rabbit muscle enolase (Sigma) was added as an exogenous phosphorylation substrate before the addition of kinase reaction buffer containing 20 mmol/L HEPES (pH 7.0), 6 mmol/L magnesium chloride, 20 mmol/L sodium orthovanadate, and 10 ACi per reaction of [g-32 P]ATP (3,000 Ci/mmol; NEN, Boston, MA). Reactions were initiated by addition of 50 AL of kinase reaction buffer and allowed to proceed for 10 min at 23jC. The reaction was stopped by the addition of 3Â Laemmli's sample buffer. For analysis of c-Src after kinase assay, samples were subjected to 8% SDS-PAGE followed by 1 h fixation in methanol/water/acetic acid (5:5:1). The gel was dried and radioactive bands were detected by autoradiography and quantitated on a Bio-Rad Personal FX PhosphorImager (Bio-Rad, Hercules, CA).
Results c-Src Binds Similar Amounts of the K303R Mutant ERA and WT ERA
Previous reports have shown that c-Src and the ERa interact in a protein complex (16, 18) . Therefore, we first sought to determine if the K303R-ERa mutation alters the ability of ERa to bind with c-Src. MCF-7 cells were treated with or without 10 À9 mol/L estrogen for 10 min and then lysed. ERa (Fig. 1A and B, lanes 1 and 2) or c-Src (Fig. 1A and B, lanes 3 and 4) was subjected to immunoprecipitation followed by immunoblot for c-Src (Fig. 1A) and ERa (Fig. 1B) . In the absence of estrogen, ERa and c-Src are in a protein complex (Fig. 1A and B, lanes 1 and 3) . Treatment with estrogen did not increase the amount of protein in the complex (Fig. 1A and B, lanes 2 and 4) . Similar amounts of starting protein are shown in the whole-cell lysates in Fig. 1A and B (lanes 5 and 6) . These data show that ERa and c-Src are in a hormone-independent complex that was not altered by short-term treatment with estrogen. Figure 1C Fig. 1C (bottom) . These results confirm that ERa forms a complex with c-Src that is independent of hormone treatment and that the K303R-ERa mutation does not seem to alter this complex.
c-Src Kinase Activity Is Elevated in K303R-ERAÊ xpressing Cells To determine if cells expressing WT ERa or the mutant ERa have similar levels of c-Src kinase activity, we next analyzed the c-Src kinase activity and tyrosine phosphorylation of the c-Src 416 residue. A c-Src -specific in vitro immunocomplex kinase assay was done as previously described (22) and a representative assay is shown in Fig. 2A . In the absence of estrogen, WT ERa -expressing cells showed a low basal level of c-Src kinase activity as shown by phosphorylation of the exogenous substrate enolase (Fig. 2A, lane 1) . When cells were treated with estrogen for 10 min, kinase activity was increased by 15% ( Fig. 2A, lane 2) . In contrast, K303R-ERa -expressing cells showed an elevated basal level of c-Src activity that was 30% higher (Fig. 2A, lane 3) when compared with WT ERa -expressing cells. This elevated kinase activity was not further increased by estrogen treatment. To confirm the elevated c-Src kinase activity in K303R-ERa versus WT ERa -expressing cells, c-Src was immunoprecipitated and the levels of pY416 and total pY content of c-Src was examined using immunoblot (Fig. 2B) . Treatment with estrogen resulted in a 1.7-fold increase in phosphorylation at Y416, and a 1.7-fold increase in total tyrosine phosphorylation of c-Src in WT ERa -expressing cells (Fig. 2B; lane 1  versus lane 2) . Consistent with its observed increased basal kinase activity, K303R-ERa -expressing cells exhibited a 1.4-fold increase in basal c-Src pY416 and a 1.7-fold increase in total phosphorylation (Fig. 2B, lane 3) . c-Src and ERa Synergism the c-Src -specific inhibitor caused a complete ablation of phosphorylation at Y416 of c-Src (Fig. 3A, lanes 3 -7) . Even in the presence of estrogen, AZD0530 caused a similar reduction in c-Src phosphorylation (Fig. 3A, lane 8) . Thus, estrogen did not significantly alter the dose of c-Src inhibitor required to inhibit c-Src phosphorylation. To show that the reduced c-Src tyrosine phosphorylation correlated with reduced c-Src kinase activity, a downstream target of c-Src, Fak, was analyzed for Y861 of Fak. Levels of pY861 of Fak correlates with the levels of pY416 of c-Src (Fig. 3A, middle) , and doses as low as 10 nmol/L of AZD0530 caused a marked reduction in Fak phosphorylation. Estrogen did not affect the ability of pYFak to be reduced by AZD0530. Levels of tubulin (bottom) show equivalent loading. These data confirm that inhibition of c-Src pY416 levels reduced c-Src kinase activity and that AZD0530 was an effective inhibitor of c-Src kinase activity. Additionally, we show that pharmacologic inhibition of c-Src signaling is not altered by short-term estrogen treatment.
K303R-ERa -expressing cells showed constitutively activated c-Src kinase; thus, we wanted to determine if increased c-Src inhibitor would be required to block c-Src signaling in WT ERa versus K303R-ERa -expressing cells. WT ERa -and WT ERa -expressing cells were pretreated with 0.01 or 0.1 Amol/L of AZD0530 for 30 min followed by 10 min of estrogen treatment. Cells were lysed, separated by SDS-PAGE, and whole-cell lysates were analyzed by immunoblot. Phosphorylation of c-Src at Y416 was partially blocked with 0.01 Amol/L and completely inhibited with 0.1 Amol/L AZD0530 (Fig. 3B, lanes 1 versus lanes 2 and 3) . Even with estrogen treatment, 0.1 Amol/L of the inhibitor blocked 40% of the c-Src phosphorylation (Fig. 3B, lanes 4  versus lanes 5 and 6) . K303R-ERa -expressing cells also showed reduced c-Src pY416 in the presence of AZD0530 (Fig. 3B, lanes 7 versus lanes 8 and 9) that was not affected by estrogen treatment (Fig. 3B, lanes 10 versus lanes 11 and  12) . c-Src Inhibition of Anchorage-Dependent Growth It is well known that estrogen treatment stimulates mitogenesis and cell growth in ERa-positive breast cancer cells. Because estrogen did not alter the ability of AZD0530 to block c-Src phosphorylation, we sought to examine the effectiveness of c-Src on estrogen-stimulated cell growth. We first tested the ability of AZD0530 to block anchoragedependent growth; the IC 50 values of multiple cell lines treated with estrogen are shown in Table 1 . All cells showed a dose-dependent growth inhibition induced by AZD0530 (data not shown). MCF-7 cells exhibited an IC 50 of 0.47 Amol/L, and the IC 50 was significantly increased 4.5-fold (P < 0.001, t test) in the presence of 10 À9 mol/L estrogen (Table 1) . Additionally, WT ERa -expressing cells also showed an IC 50 of 0.45 Amol/L, which was not statistically significant compared with the parental MCF-7 cells (P > 0.1, t test). This IC 50 was increased 4-fold in the presence of estrogen (P < 0.001, t test). Thus, estrogen signaling results in the requirement for higher concentrations of the c-Src inhibitor to block cell growth. K303R-ERa -expressing cells exhibited a higher basal IC 50 value that was significantly higher than MCF-7 or WT ERaexpressing cells (P < 0.01, t test). The addition of estrogen to mutant expressing cells increased the IC 50 value by only 1.4-fold (Table 1) . Thus, when cells are expressing the mutant ERa, and hence have increased basal c-Src kinase activity, higher levels of c-Src inhibitor were required to Table 1 ). This result shows that estrogen signaling through the ERa is required to increase the amount of AZD0530 to effect cell growth. Higher concentrations of AZD0530 may be needed to affect the K303R-ERa mutant. These results predict that the presence of estrogen in ERa-positive cells or expression of the K303R-ERa mutant may alter the efficacy of c-Src inhibitors.
Estrogen Treatment Reduces the Ability of AZD0530 to Inhibit Anchorage-Independent Growth Increased signaling through ERa decreases the ability of the AZD0530 c-Src inhibitor to reduce anchoragedependent growth, and c-Src inhibitors have previously been shown to reduce HER2 and c-Met-mediated anchorageindependent growth (24, 25) . We next wanted to determine whether inhibition of c-Src would also reduce estrogeninduced, anchorage-independent growth. Cells were grown in 0.3% soft agar with varying concentrations of AZD0530 added as described in Materials and Methods. Under basal conditions, estrogen treatment stimulated a 1.5-fold increase in the ability of MCF-7 cells to form colonies in soft agar (P < 0.01, t test; Fig. 4A ). Inhibition of c-Src kinase activity caused a dose-dependent reduction in soft-agar colony formation as shown in Fig. 4A . Although 1 Am was effective at reducing both basal and estrogenstimulated colony formation (P < 0.01, t test), 3 Am of AZD0530 completely abolished the ability of MCF-7 cells to form colonies in soft agar (P < 0.001, t test; Fig. 4A ). Thus, in the presence of estrogen, more AZD0530 was required to block soft-agar colony-forming ability.
WT ERa -or K303R-ERa -expressing cells were also tested for their ability to form colonies in soft agar (Fig. 4B) . In the absence of AZD0530, basal growth was not statistically different between WT ERa -and K303R-ERa -expressing cells. Estrogen stimulated a 2.3-fold increase in colony formation in WT ERa cells (P < 0.01, t test), but a 4-fold increase in K303R-ERa -expressing cells (P < 0.01, t test; Fig. 4 ). Similar to MCF-7 cells, both WT ERa -and K303R-ERa -expressing cells showed a dose-dependent reduction in soft-agar colony formation following c-Src inhibition (Fig. 4B) , and the presence of estrogen required more inhibitor to block soft-agar colony formation. These data show that c-Src inhibition blocked anchorage-independent growth of breast cancer cells and that more drug was required to block cell growth in the presence of estrogen in K303R-ERa -expressing breast cancer cells.
Recently, Hiscox et al. (26) reported that AZD0530 blocked invasion and migration of tamoxifen-resistant MCF-7 cells. Therefore, we next determined if c-Src inhibition combined with tamoxifen could synergistically inhibit the anchorage-independent growth of MCF-7 cells. Figure 5 (columns 1 -5) again shows a dose-dependent reduction in soft-agar colony-forming ability, confirming our previous results. Additionally, tamoxifen treatment also showed a dose-dependent reduction in soft-agar colony-forming ability (Fig. 5, columns 6 -8) . Because 3 Amol/L AZD0530 and 10 À7 mol/L tamoxifen were each >90% effective at inhibiting the anchorage-independent growth of MCF-7 cells, we next tested suboptimal doses of these drugs in combination to determine if additive or synergistic effects could be achieved. Growing cells in the presence of 10 À8 mol/L tamoxifen almost completely inhibited basal colony formation but not estrogen-induced colony formation (Fig. 5, column set 7 ). Tamoxifen (10 À9 mol/L) alone only inhibited 34% of basal growth, and 24% of estrogen-induced growth (Fig. 5 ). Low concentrations (0.1 and 1 Amol/L) of AZD0530 alone gave 36% and 70% inhibition, respectively, when used alone (Figs. 4A and 5), and these doses of AZD0530 completely inhibited basal colony formation in combination with low doses (10 À8 or 10 À9 mol/L) of tamoxifen (Fig. 5,  columns 9 -12) .
A model-free test for synergy was used based on two simultaneous one-sided t tests comparing each of the singleagent doses of AZD0530 and tamoxifen with a combined regimen of the two drugs at suboptimal doses (21) . Specifically, the comparison between AZD0530 at 1 Amol/L and AZD0530 at 0.1 Amol/L plus tamoxifen (10 À9 mol/L) was statistically significant (P < 0.0001). Likewise, the second comparison between tamoxifen at 10 À8 mol/L was compared with AZD0530 at 0.1 Amol/L plus tamoxifen at 10 À9 mol/L was also found to be statistically significant (P = 0.022), indicating synergistic effects between the two drugs. Finally, estimates of the differences between specific drug combinations versus control groups were calculated based on an ANOVA model with interaction terms between the two drugs. The mean difference in the number of colonies between AZD0530 at 0.1 Amol/L plus tamoxifen at 10 À9 mol/L versus the control group was 139.3 (95% confidence interval, 124.1 -154.5, P < 0.0001). This effect was more than the combined effect of either drug alone compared with the control group. However, when cells were treated with estrogen, the interactions were not significant. Thus, both AZD0530 and tamoxifen were effective at reducing soft-agar colony formation; but here we show that combinations of these inhibitors were more effective than either inhibitor alone and estrogen was able to block this effect.
Discussion
Estrogen-induced activation of ERa has been shown to activate the c-Src signaling pathway (17) . ERa and c-Src bind in a protein complex that has been proposed to involve other proteins such as modulator of nongenomic activity of ER and phosphatidylinositol 3-kinase (16, 27, 28) . Our studies showed hormone-independent interactions between ERa and c-Src that were not altered by estrogen or the K303R-ERa mutation. Although their interaction did not change, K303R-ERa -expressing cells showed a 30% increase in basal c-Src kinase activity, which was correlated with increased phosphorylation of c-Src. We have previously reported that the K303R-ERa mutant is hypersensitive to very low levels of estrogen (5), and here we showed that expression of the mutant ERa led to higher basal c-Src kinase activity in breast cancer cells. Thus, although this mutation in ERa did not seem to alter the ability of the receptor to bind with c-Src, as has been shown for the TIF-2 coactivator (5), it did alter the ability of the receptor to phosphorylate and activate c-Src.
Although c-Src activity was elevated, this increase was very low, and therefore its effects on the cell could be minimal; thus, a c-Src inhibitor was used to address this question. Anchorage-dependent growth analysis showed that estrogen-stimulated growth required higher concentrations of AZD0530 to achieve the same inhibitory effects seen in the nonstimulated systems. This result was also confirmed in anchorage-independent growth assays. From the anchorage-dependent and anchorageindependent growth data, one would have expected that estrogen stimulation would increase c-Src phosphorylation as it did under basal conditions. However, in our model system, estrogen did not affect inhibitor blockade of c-Src phosphorylation. Estrogen signaling has been shown to activate a number of prosurvival pathways, including Bcl-2 (29), caspase regulation (30) , and calcium homeostasis (31) to name a few. Estrogen signaling may be activating alternative survival and growth pathways that can bypass the requirement for c-Src activation, hence an estrogen-induced survival effect. Cells expressing the mutant receptor had an elevated basal IC 50 ; thus, more drug may be required to block the basal in vitro growth rate of K303R-ERa -expressing cells. Additionally, estrogen only stimulated a <1.5-fold increase in the IC 50 required to inhibit the K303R-ERa -expressing cells. Although the moderately increased c-Src activity in K303R-ERa -expressing cells was enough to alter the basal biology of the cells in serum-free conditions as shown by the growth assays, it may also raise the basal level of signaling to a threshold level, thereby serving to ''prime'' the cell for other activating stimuli such as estrogen or growth factor signaling. One such example has been shown in PC12 cells in which chemotactic migration is not stimulated until a threshold level of extracellular signal-regulated kinase 1/2 signaling has been reached (32) . Thus, the increased c-Src activity observed in the K303R-ERa -expressing cells may not have crossed the threshold level required to cause other biological effects, but it may be at the threshold and thus primed for a stimulus.
It has recently been shown that tamoxifen-resistant MCF-7 cells were more sensitive to AZD0530 than their nonresistant counterparts (26) . We therefore tested the effect of combining suboptimal doses of tamoxifen and AZD0530 in soft-agar growth assays. Our data showed that the addition of AZD0530 made the cells more sensitive to growth inhibition by tamoxifen. Hiscox et al. (26) also showed that in tamoxifen-resistant epidermal growth factor receptor overexpressing MCF-7 cells, the combination of AZD0530 and the epidermal growth factor receptor inhibitor gefitinib blocked migration and invasion in an additive manner. A number of studies have shown that inhibiting c-Src activity in breast cancer cells blocks estrogen-induced cell cycle progression and mitogenesis (33, 34) . Additionally, c-Src inhibitors have also been shown to block estrogen-induced migration in endometrial cells (35) and disrupt adherans junctions in endothelial cells (36) . Thus, multiple biological phenotypes required for tumor progression may be converging and signaling through c-Src. It remains to be determined if c-Src inhibitors can inhibit or reverse tamoxifen resistance in vivo. Although these data support investigating the potential therapeutic benefit of c-Src kinase inhibition in women with ERapositive breast cancer, a rational approach evaluating the c-Src activity, ERa levels, and perhaps the K303R mutation status is warranted. Although the influence of circulating estrogen still requires further elucidation, the data suggest that strategies combining drugs that lower estrogen signaling with a c-Src kinase inhibitor could provide a rational approach to treating these patients.
